JP2012506896A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506896A5
JP2012506896A5 JP2011533714A JP2011533714A JP2012506896A5 JP 2012506896 A5 JP2012506896 A5 JP 2012506896A5 JP 2011533714 A JP2011533714 A JP 2011533714A JP 2011533714 A JP2011533714 A JP 2011533714A JP 2012506896 A5 JP2012506896 A5 JP 2012506896A5
Authority
JP
Japan
Prior art keywords
meta
compound
och
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533714A
Other languages
English (en)
Japanese (ja)
Other versions
JP5490811B2 (ja
JP2012506896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064243 external-priority patent/WO2010049466A1/en
Publication of JP2012506896A publication Critical patent/JP2012506896A/ja
Publication of JP2012506896A5 publication Critical patent/JP2012506896A5/ja
Application granted granted Critical
Publication of JP5490811B2 publication Critical patent/JP5490811B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533714A 2008-10-30 2009-10-29 アポaに対して活性なチエノトリアゾロジアゼピン誘導体 Expired - Fee Related JP5490811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
EP08167982.1 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (3)

Publication Number Publication Date
JP2012506896A JP2012506896A (ja) 2012-03-22
JP2012506896A5 true JP2012506896A5 (enExample) 2012-12-20
JP5490811B2 JP5490811B2 (ja) 2014-05-14

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533714A Expired - Fee Related JP5490811B2 (ja) 2008-10-30 2009-10-29 アポaに対して活性なチエノトリアゾロジアゼピン誘導体

Country Status (11)

Country Link
US (1) US8569288B2 (enExample)
EP (1) EP2362876B1 (enExample)
JP (1) JP5490811B2 (enExample)
KR (1) KR101633742B1 (enExample)
CN (1) CN102292341B (enExample)
AU (1) AU2009309691B2 (enExample)
BR (1) BRPI0914406A2 (enExample)
CA (1) CA2741934C (enExample)
EA (1) EA018620B1 (enExample)
ES (1) ES2448567T3 (enExample)
WO (1) WO2010049466A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体の使用
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
PT3157928T (pt) 2014-06-20 2019-05-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN112312916A (zh) 2018-06-13 2021-02-02 戴布里股份公司 缩合三氮杂卓衍生物的制备及其作为bet抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
BR9610390A (pt) 1995-09-09 1999-07-06 Hoffmann La Roche O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Similar Documents

Publication Publication Date Title
JP2012506896A5 (enExample)
JP2010077141A5 (enExample)
JP2014500861A5 (enExample)
JP2014508811A5 (enExample)
JP2014515013A5 (enExample)
JP2013508279A5 (enExample)
JP2012502037A5 (enExample)
JP2013032389A5 (enExample)
JP2013545785A5 (enExample)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2013544860A5 (enExample)
JP2010509379A5 (enExample)
JP2010527913A5 (enExample)
JP2010501474A5 (enExample)
JP2014521744A5 (enExample)
JP2009535307A5 (enExample)
JP2011519854A5 (enExample)
JP2013513607A5 (enExample)
JP2013503846A5 (enExample)
JP2011518833A5 (enExample)
JP2011504903A5 (enExample)
JP2008533007A5 (enExample)
JP2012532883A5 (enExample)
JP2007302689A5 (enExample)
JP2013533253A5 (enExample)